BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 15534087)

  • 1. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.
    Benoy IH; Salgado R; Van Dam P; Geboers K; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
    Clin Cancer Res; 2004 Nov; 10(21):7157-62. PubMed ID: 15534087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
    Zhang GJ; Adachi I
    Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.
    Benoy IH; Salgado R; Elst H; Van Dam P; Weyler J; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
    Breast Cancer Res; 2005; 7(2):R210-9. PubMed ID: 15743502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The influence of the hemoglobin concentration on the hematogenous tumor cell dissemination at the time of the initial diagnosis of breast cancer].
    Janni W; Strobl B; Rack B; Rjosk D; Schindlbeck C; Hantschmann P; Kentenich C; Sigg W; Zerzer M; Sommer H
    Dtsch Med Wochenschr; 2002 Jan; 127(3):71-7. PubMed ID: 11797143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy.
    Bozcuk H; Uslu G; Samur M; Yildiz M; Ozben T; Ozdoğan M; Artaç M; Altunbaş H; Akan I; Savaş B
    Cytokine; 2004 Jul 21-Aug 7; 27(2-3):58-65. PubMed ID: 15242694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?
    Lang JE; Hall CS; Singh B; Lucci A
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1463-72. PubMed ID: 17944570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients.
    Kozłowski L; Zakrzewska I; Tokajuk P; Wojtukiewicz MZ
    Rocz Akad Med Bialymst; 2003; 48():82-4. PubMed ID: 14737948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
    Braun S; Schlimok G; Heumos I; Schaller G; Riethdorf L; Riethmüller G; Pantel K
    Cancer Res; 2001 Mar; 61(5):1890-5. PubMed ID: 11280743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6, multidrug resistance protein-1 expression and response to paclitaxel in women with metastatic breast cancer: results of cancer and leukemia group B trial 159806.
    Rincon M; Broadwater G; Harris L; Crocker A; Weaver D; Dressler L; Berry D; Sutton L; Michaelson R; Messino M; Kirshner J; Fleming G; Winer E; Hudis C; Appel S; Norton L; Muss H;
    Breast Cancer Res Treat; 2006 Dec; 100(3):301-8. PubMed ID: 16773437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of serum IL-18 and nitric oxide activity in breast cancer patients at operable stage.
    Günel N; Coskun U; Sancak B; Hasdemir O; Sare M; Bayram O; Celenkoglu G; Ozkan S
    Am J Clin Oncol; 2003 Aug; 26(4):416-21. PubMed ID: 12902898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse.
    Bidard FC; Vincent-Salomon A; Gomme S; Nos C; de Rycke Y; Thiery JP; Sigal-Zafrani B; Mignot L; Sastre-Garau X; Pierga JY;
    Clin Cancer Res; 2008 Jun; 14(11):3306-11. PubMed ID: 18519757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
    Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
    Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.
    Müller V; Stahmann N; Riethdorf S; Rau T; Zabel T; Goetz A; Jänicke F; Pantel K
    Clin Cancer Res; 2005 May; 11(10):3678-85. PubMed ID: 15897564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.
    Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(2):113-21. PubMed ID: 18237248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of a panel of mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer.
    Varangot M; Barrios E; Sóñora C; Aizen B; Pressa C; Estrugo R; Lavigna R; Musé I; Osinaga E; Berois N
    Oncol Rep; 2005 Aug; 14(2):537-45. PubMed ID: 16012742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in the bone marrow of patients with breast cancer.
    Chavez-Macgregor M; Aviles-Salas A; Green D; Fuentes-Alburo A; Gómez-Ruiz C; Aguayo A
    Clin Cancer Res; 2005 Aug; 11(15):5396-400. PubMed ID: 16061853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients.
    Farmen RK; Nordgård O; Gilje B; Shammas FV; Kvaløy JT; Oltedal S; Heikkilä R
    Breast Cancer Res Treat; 2008 Mar; 108(2):251-8. PubMed ID: 17492378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
    Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
    Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.